Home » XTL BIOPHARMACEUTICALS TRANSFERS HEPEX-B PROGRAM TO CUBIST PHARMACEUTICALS
XTL BIOPHARMACEUTICALS TRANSFERS HEPEX-B PROGRAM TO CUBIST PHARMACEUTICALS
XTL Biopharmaceuticals today announced that the transition of HepeX-B development activities from XTLbio to Cubist Pharmaceuticals (NASDAQ: CBST) has been completed, and that, accordingly, Cubist will not make collaborative support payments which would otherwise have been due to XTLbio in 2005 of $1 million. The collaborative support payments were established to cover XTLbio overhead associated with managing the HepeX-B program. Cubist will reimburse XTLbio for all direct costs associated with the program incurred at the request of Cubist.
Globes Online (http://www.globes.co.il/serveen/globes/docview.asp?did=943174&fid=942)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May